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Abstract: 
Current approaches to generate core-shell nanoparticles for biomedical applications are limited 
by factors such as synthetic scalability and circulatory desorption of cytotoxic surfactants. 
Developments in controlled radical polymerisation, particularly in dispersed states, represent a 
promising method of overcoming these challenges. In this work, well-defined PEGylated 
nanoparticles were synthesised using reversible addition fragmentation chain transfer emulsion 
polymerisation to control particle size and surface composition, and were further characterised 
with light scattering, electron microscopy and size exclusion chromatography (SEC). 
Importantly, the nanoparticles were found to be tolerable both in vitro and in vivo, without the 
need for any purification after particle synthesis. Pharmacokinetic and biodistribution studies 
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in mice, following intraperitoneal injection of the nanoparticles, revealed a long (>76 h) 
circulation time and accumulation in the liver.  
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1. Introduction  
 
Polymeric nanoparticles are well established as platforms for drug delivery and bio-imaging 
applications.[1, 2] Their large size promotes extended circulation times[3] and passive tumour 
accumulation through the enhanced permeability and retention (EPR) effect.[4, 5] 
Encapsulation/conjugation of chemotherapeutic agents inside these vehicles protects them 
from degradation by physiological processes after administration, while also facilitating their 
transport across the cellular membrane. Additionally, their high surface functionality can be 
exploited by attaching specific targeting moieties (antibodies[6], peptides[7], or glycosylated 
moieties[8, 9]). These properties can lead to higher therapeutic efficacy, tumour selectivity and 
reduced side effects for nanoparticle drug delivery vectors, in comparison to their molecular 
drug counterparts. [10]  
 
In nanomedicine, and particularly for cancer therapy, polymeric nanoparticles are generally 
engineered to have diameters between 20 - 200 nm (to exploit the EPR effect), [4, 5, 11] a 
hydrophobic core for high drug loading efficiency, [12] and a cyto-compatible corona to reduce 
toxicity.[13] These properties can be achieved through a multitude of methods, including self-
assembly of amphiphilic block-copolymers,[14, 15] or traditional emulsion polymerisation.[16] 
These synthetic approaches have potential disadvantages which may limit their clinical use. 
For instance, self-assembly of block copolymers is typically performed at low concentrations, 
small scales (2-5 mg mL-1) and in the presence of cytotoxic organic solvents (DMF, THF or 
Methanol), affecting safety and synthetic reproducibility.[17] In contrast, emulsion 
polymerisation is highly scalable and is conventionally performed in aqueous media. However, 
it requires stabilisation using traditional surfactants, which can be highly cytotoxic. 
Furthermore, the low circulatory concentration of therapeutic nanomaterials after injection may 
cause the release or disassembly of amphiphilic molecules (either surfactants or block 
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copolymers). This can reduce the biocompatibility and increase the clearance rate of materials 
produced using both methods, which can have an impact in their therapeutic efficacy.[18] This 
can be overcome with meticulous design of covalently bound branched/brush-like polymers 
(unimolecular micelle)[19-21], however, achieving the large sizes (20-200 nm) and scales[17] 
required for these application through this method is non-trivial.  
 
Reversible addition fragmentation chain transfer (RAFT) emulsion polymerisation provides an 
elegant solution to some of these problems by combining the advantages of traditional emulsion 
polymerisation (fast polymerisation rates, green/aqueous conditions and high scalability) with 
the hallmarks of controlled radical polymerisation (narrow and tuneable molecular weight 
distributions, block copolymer synthesis and functional end group fidelity).[22, 23] During this 
process, amphiphilic di-block macromolecular RAFT (macro-RAFT) agent stabilisers are 
assembled into micelles, with the thiocarbonylthio group within the core. These are then chain 
extended during the emulsion polymerisation with hydrophobic monomer (oil phase), resulting 
in ‘frozen’ uniform core-shell latex nanoparticles where the shell is comprised of the 
hydrophilic section of the stabilising agent. Nanoparticles prepared using this approach are 
adapted for biomedical applications, as the shell is covalently attached and cannot desorb from 
the particle during circulation. Advantageously, this process is performed in the absence of 
organic solvents (aqueous conditions), is highly scalable, and the stabiliser can be designed to 
impart biocompatibility or other additional functionality.  
 
Nevertheless, most reports on RAFT emulsion polymerisation focus on their synthesis (kinetics 
and morphology),[22, 24-28] with only a few notable studies exploiting this technique to generate 
nanoparticles aimed at biomedical applications. For example, Stenzel and co-workers used an 
amphiphilic poly(glucose methacrylamide)-b-polystyrene macro-RAFT agent to generate 
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glycosylated nanoparticles, which displayed high affinity for E. coli. [29] Whereas, Wang and 
co-workers used RAFT emulsion polymerisation to control the monomer composition of the 
nanoparticle shell, yielding a system which release rate of a model hydrophobic drug  
(indomethacin) could be tuned with pH.[30] Furthermore, our group have illustrated the 
potential for surface modification of polyacrylamide stabilised polystyrene nanoparticles 
synthesised from RAFT emulsion, initially as micro-RNA carriers, and also for fluorescent 
labelling for studies in vitro and in vivo.[31, 32] In addition, we recently used this approach to 
generate well-defined mannose coated nanoparticles able to interact with lectin Concanavalin 
A.[33] Nonetheless, these nanoparticle systems required extensive dialysis purifications, which 
reduces their scalability potential. Moreover, their suitability in complex biological organisms 
still remains mostly unknown, with little information reported about these nanoparticles in 
cellular assays or live animal models.  
 
Herein we report the synthesis of a series of core-shell polymeric nanoparticles via RAFT 
emulsion polymerisation purposely designed to impart high biocompatibility without the need 
of post-synthesis purification. The nanoparticles were characterised with light scattering, 
electron microscopy and size exclusion chromatography. Their toxicity was then evaluated in 
vitro on a colorectal carcinoma cell line (Caco-2), and in vivo on mouse models. Finally, a near-
infrared (NIR) probe, Cyanine-7.5, was encapsulated into the nanoparticles, and preliminary 
pharmacokinetics and biodistribution were studied using an in vivo fluorescence imager. 
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2. Results and Discussion 
 
Scheme 1 Preparation of n-BA and t-BA macro-RAFT agents via solution RAFT 
polymerisation, and subsequent RAFT emulsion polymerisation to generate n-BA and t-BA 
nanoparticles.  
 
2.1. Macro-RAFT agent synthesis and characterisation 
Macro-RAFT agents poly[(poly(ethylene glycol methyl ether acrylate)8-block-(n-butyl 
acrylate)8] (P(PEGA)8-b-P(n-BA)8) and poly[(poly(ethylene glycol methyl ether acrylate)8-
block-(t-butyl acrylate)8] (P(PEGA)8-b-P(t-BA)8) were synthesised in two steps (Scheme 1), 
using previously described conditions.[33] Initially, polymerisation of PEGA was conducted in 
the presence of RAFT agent PABTC, and subsequently chain extended with tert-butyl acrylate 
(t-BA) or n-butyl acrylate (n-BA) at 70°C. In both cases, CHCl3-SEC indicated narrow molar 
mass distributions (Đ < 1.2; Figure S1, Table S1), with shifts towards higher molecular weight 
after chain extension we found 1H NMR spectra confirmed excellent agreement between 
theoretical and observed molar masses (Figure S2). Furthermore, dynamic light scattering 
(DLS) indicated the formation of micelles 6 nm in diameter for aqueous solutions of both P(n-
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BA) and P(t-BA) macro-RAFT agents (Figure S3). -potential measurements indicated 
negatively charged surfaces (~-10 mV), imparted by the carboxylate R group of PABTC (Table 
1). 
 
2.2. Nanoparticle synthesis via RAFT emulsion polymerisation 
Nanoparticles of different sizes were synthesised using RAFT emulsion polymerisation 
according to previously described methods (Scheme 1).[33]. Briefly, the macro-RAFT agent and 
thermal initiator ACVA were dissolved in deionised water, sealed and purged with N2, then 
deoxygenated monomer (t-BA for t-BA macro-RAFT agent, or n-BA for n-BA macro-RAFT 
agent) was added in batch, without feeding. Emulsions were homogenised and heated at 70°C 
for 3 h. Emulsion polymerisations were performed with five different DPtarget (50, 75, 100, 150 
and 200) for the third, core forming block, resulting in a library of five P(t-BA) and five P(n-
BA) core-shell nanoparticles. Syntheses were performed at up to 8.4 wt% monomer at 10 mL 
scales (84 mg mL-1), which could be easily scaled up to multi-gram reactions.[34] Full monomer 
conversion was attained in under 3 h, due to the well-established compartmentalisation effects 
found in emulsion polymerisation. This is particularly useful in a biomedical context, as 
residual monomer is known to be highly cytotoxic.[35] Our system can therefore be used without 
any further purification, as the polymerisations are performed in water. It should be noted that 
RAFT emulsion polymerisation procedures can be performed directly from the hydrophilic 
homopolymer, with the diblock formation occurring in situ. However in preliminary 
experiments we found this gave broad dispersity latexes and poorer molecular weight control 
(data not shown). SEC chromatograms of the dissolved nanoparticles indicated successful 
chain extension, with a significant shift from the macro-RAFT agent traces. Nonetheless, 
chromatograms exhibited three distinct populations: a small high molecular weight shoulder 
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(due to branching or bimolecular termination), a second low molecular weight population of 
unconsumed macro-RAFT agent, and a main narrow population of the targeted polymer 
(Figure 1a and 1b). As expected for controlled radical polymerisations, increasing the DPtarget 
resulted in larger experimental molar masses (10,200 to 30,700 g mol-1 for P(t-BA) and 11,500 
to 25,700 g mol-1 for P(n-BA)) determined by SEC. DLS traces revealed narrow monomodal 
size distributions (PDi ≤ 0.07; Table 1), whereby particle diameter increased from 31 to 119 
nm for P(t-BA) and 28 to 130 nm for P(n-BA) nanoparticles, in accordance with DPtarget (Figure 
1c and 1d). This highlights the fine relationship between unimer molecular weight and particle 
size, which is a useful feature when designing nanoparticles for biomedical applications, as 
particle size is known to heavily influence cellular uptake and biodistribution.[36]  Nanoparticle 
size and morphology were confirmed using Cryo-TEM, revealing spherical particles with 
diameters similar to those determined with light scattering (Figure 2). Furthermore, due to the 
carboxylic acid moiety on the surface, all nanoparticles displayed negative -potential values 
between -35 and -50 mV, known to reduce toxicity and specific interactions.[36] Full 
characterisation data of the nanoparticles can be found in Table 1. 
 
Table 1 Characterisation of the P(n-BA) and P(t-BA) nanoparticles used in this study. 
 
aRefers to the target DP of RAFT emulsion polymerisations performed to obtain the third core 
forming block. bDetermined by DLS. cDetermined with a Zetasizer. dDetermined using 
Core 
polymer 
DPtargeta 
Dhb 
(nm) 
PDib 
ζc  
(mV) 
Mn,th 
(g mol-1)d 
Mn,SEC 
(g mol-1)e 
Mw,SEC 
(g mol-1)e 
Ðe 
Ma 
(Mg mol-1)f 
Naggg Nagg,thh 
P(n-BA) 
200 130 0.05 -47.3 30700 25700 48600 1.86 1060  21800 22500 
150 93 0.06 -37.8 24300 22500 34000 1.60 350  10300 10100 
100 75 0.06 -35.4 17900 18400 24400 1.39 157  6600 7400 
75 50 0.06 -37.1 14700 14200 18500 1.35 21 1200 2700 
50 28 0.06 -34.2 11500 11500 13300 1.22 6.9  520 600 
P(t-BA) 
200 119 0.05 -48.5 30700 30700 47000 1.54 777  16500 17300 
150 86 0.05 -45.1 24300 22000 34900 1.58 283  8100 8300 
100 65 0.06 -39.2 17900 16500 24400 1.47 127  5200 5100 
75 49 0.06 -42.6 14700 13300 17600 1.32 37  2100 2700 
50 31 0.07 -37.4 11500 10200 12600 1.23 13  1000 800 
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Equation 1  eDetermined by CHCl3-SEC (values are obtained by integrating the whole region, 
including all three peaks), calibrated with PMMA standards. f Determined by SLS. g Calculated 
using Equation S1-4.hCalculated using Equation 3 and 4. 
 
 
To elicit if the P(PEGA) block remained at the particle surface, we used a PEG selective 
aggregation assay, based on the well-known property of PEG as a tannin binding agent.[37-39] 
This operates on a similar basis to lectin-glycopolymer assays, where addition of an agent 
which can bind multiple substrates (nanoparticles, polymers etc.) induces an increase in 
turbidity/absorbance, caused by aggregation of particles. Interestingly, a rapid increase in 
absorbance (at 500 nm) was observed when nanoparticles (both P(t-BA) and P(n-BA)) were 
treated with tannic acid (Figure S4), suggesting high availability of PEG in their surface. 
Unfortunately, this cannot be used to quantify how many chains are available at the corona. 
This was further studied using static light scattering (SLS), which allows to determine the 
weight average molar mass of a whole nanoparticle, and therefore, the number of polymer 
building blocks per particle (Nagg). Scattering profiles of all ten nanoparticle suspensions (at 
four different concentrations) were acquired across 8 angles (Figure S5). Larger apparent 
particle molar masses (Ma) were observed with increasing nanoparticle diameter for both P(t-
BA) and P(n-BA) nanoparticles. By dividing the Ma values obtained by the Mw of their 
respective unimers (obtained previously from SEC), we could approximate the number of 
unimers per particle (Nagg). Surprisingly, Nagg increased dramatically with larger particle sizes, 
ranging from < 1000 for the smallest nanoparticles, up to > 15,000 for the largest (Table 1), 
and show excellent agreement with theoretical Nagg values (Equation 3 and 4; Table 1). This 
trend observed can be rationalised as larger nanoparticles have more surface area, hence require 
greater stabilisation than smaller nanoparticles. Moreover, our results suggests that some level 
of rearrangement of the macro-RAFT agents occurs during the RAFT emulsion polymerisation 
process, leading to different Nagg depending on particle size.
 [40] 
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Figure 1. CHCl3-SEC chromatograms depicting the increasing DPtarget chain extensions of (A) 
P(PEGA)8-b-P(n-BA)8 with n-butyl acrylate and (B) P(PEGA)8-b-P(t-BA)8 with t-butyl 
acrylate.  Chromatograms obtained by dissolving dried nanoparticles in SEC eluent. DLS traces 
(number distribution) of all (C) poly(n-butyl acrylate) and (D) poly(tert-butyl acrylate) 
nanoparticles and their respective macro-RAFT agents (dashed grey lines) sizes at 25˚C diluted 
1/1000 in pure water.       
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Figure 2. Cryo-TEM images of undiluted P(t-BA) (top row) and P(n-BA) (bottom row) 
nanoparticles deposited on lacey carbon coated grids.   
2.3. In vitro and in vivo biocompatibility 
 
 
Figure 3. Antiproliferative activity of P(n-BA) (28 – 130 nm) and P(t-BA) (31 – 119 nm) on 
Caco-2 cells over 72 h at 2, 0.5, 0.2, 0.01, 0.001 and 0.0001 mg mL-1 assessed using the 
sulforhodamine B assay. Data is expressed as the arithmetic mean ± standard deviation of two 
independent experiments performed in triplicate (N=6). 
 
The biocompatibility of all ten nanoparticles was determined both in vitro and in vivo without 
prior purification. Initially, cells from a human colorectal adenocarcinoma cell line (Caco-2) 
were exposed to different concentrations of nanoparticles (2 mg.mL-1 – 100 ng.mL-1) for 72 h, 
and cell viability was measured using the sulforhodamine B (SRB) assay. None of the 
nanoparticles inhibited cell growth up to 0.5 mg mL-1. Nonetheless, the 75 nm P(n-BA), and 
all P(t-BA) nanoparticles with Dh > 31 nm reduced cell proliferation at 2 mg mL
-1 (Figure 3). 
However, this concentration is far beyond any envisaged clinical dosage for these, or other 
similar systems. 
 
A
B
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It has previously been shown that there is little particle size dependency on in vivo 
biodistribution and toxicity,[41] therefore the 49 and 86 nm P(t-BA) and, 50 and 93 nm P(n-BA) 
nanoparticles were selected as representative treatments for in vivo toxicity experiments. In a 
first experiment, wild type ICR CD1 mice were treated with a single dose (1.2 mg kg-1 and 12 
mg kg-1) or 7-day daily repeated (subchronic; injections performed for 5 days and weight 
monitored for 7 total) intraperitoneal (i.p.) injection of nanoparticles (only at the higher 
concentration) or vehicle control. Body weight, appearance of coat and clinical behaviour were 
monitored daily for a period of 7 days after administration (Figure 4). No clinical toxicity was 
apparent for any of the nanoparticles tested, both after acute or subchronic dosing. No 
statistically significant differences in body weight changes were found between nanoparticles- 
and vehicle-treated mice over the 7-day span (p = 0.15 for single injection and p = 0.15 for 
subchronic dosing). Importantly none of the individual mice showed any reduction in body 
weight or any “clinical” toxicity signs over the seven day period.  
 
The excellent tolerability observed both in vitro and indeed in vivo is likely due to the P(PEGA) 
shell present on all the nanoparticles, which is known to reduce the immune response and other 
unwanted interactions within the organism.[42] This is in accordance with a report from 
Tamanoi and co-workers, showing limited toxicity for intraperitoneally administered 
mesoporous silica nanoparticles through a full serological, haematological and 
histopathological investigation.[43] 
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Figure 4. Acute (top row) and 7-day repeated (bottom row) toxicity in mice for the 50 and 93 
nm n-BA, and 49 and 86 nm t-BA nanoparticles at both 1.2 mg kg-1 (red lines) and 12 mg kg-1 
(blue lines), measured as a function of animal body weight monitored over 7 days (N=3 for 
acute toxicity, N=6 for 7-day repeated dosing). Controls of PBS injection (green lines; N=3 for 
both acute toxicity and 7-day dosing) and non-injected (purple lines; N=2 for both acute 
toxicity and 7-day dosing) mice are also displayed. Data is reported as mean ± SEM. Arrows 
indicate administration points. 
 
2.4. Fluorescent labelling and in vivo biodistribution  
NIR fluorescence is a highly sensitive and non-invasive method to study pharmacokinetics, 
biodistribution and organ accumulation.[44] As a model study, we labelled the 50 nm P(n-BA) 
nanoparticles with NIR dye Cyanine 7.5 amine (Cy7.5), following an adapted procedure from 
Resch-Genger and co-workers.[45] This approach works by swelling the particles with ca. 10% 
organic solvent, in the presence of the hydrophobic dye, partitioning it into the core of the 
nanoparticles. The particles were then purified by extensive dialysis and analysed with 
fluorescence spectroscopy to confirm dye internalisation (Figure S6).  
 
A dilute suspension of NIR-particles (1.2 mg kg-1) was administered (i.p.) to adult male CD1 
mice, and the nanoparticle distribution was followed over 76 h using a LICOR Pearl® Trilogy 
in vivo fluorescence imager. Prior to injection, no fluorescence was observed from any part of 
the animal (Figure 5a). In contrast, a bright signal from the abdominal cavity was detected 
immediately after i.p. injection, which decreased rapidly within 2 h, thus likely reflecting 
uptake and distribution into the systemic circulation (Figure 5a and 5b, Figure S7). This was 
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followed by slow clearance, over the next 74 h (Figure 5a and 5b), with 36% of the injected 
dose being retained within the animal at the end of the experiment (76 h; Figure S7). Ex vivo 
imaging of the excised organs at 76 h after injection revealed high nanoparticle accumulation 
in the liver. Negligible amounts were found in the heart or white adipose tissue of the animal, 
while small but significant quantities were observed in the intestine, spleen and kidneys (Figure 
5c and S8). However, some of this signal might be due to direct particle adsorption to the 
peritoneal organs after i.p. injection, however some subsequent release into systemic will still 
occur. Additionally, the intestinal signal could be partly attributed to the presence of 
chlorophyll in the animal diet, resulting in faecal NIR fluorescence in non-injected mice 
(Figure S9).[46] It is unlikely, however, that diet is solely responsible for the detected intestinal 
fluorescence. A new NIR signal appears around the anus area 1 h after administration, which 
is not observable in untreated animals. Therefore, a significant proportion of the intestinal 
emission should be associated with the nanoparticles. This might suggest that our particles 
could be excreted via the gastrointestinal/ hepatobiliary system, a well-known elimination route 
for nanoparticles, as their size is above the renal filtration threshold of 4.5-5 nm.[47, 48]   
 
There are relatively few reports on the biodistribution and pharmacokinetics of 
intraperitoneally administered polymeric nanoparticles.[49, 50] Nonetheless the described 
nanoparticles can still be compared to similar studies using non-polymeric nanomaterials. For 
example, in contrast to 100 nm mesoporous silica nanoparticles (MSN), our system show far 
quicker clearance from the peritoneal cavity, (64% after 76 h compared to 0-5% after 160 h), 
but greater accumulation in the abdominal organs (liver, spleen, intestine).[43] Meanwhile, a 
similar study on gold nanoparticles revealed almost complete clearance within 24 h, with 
similar accumulation in in the liver and spleen.[51]  
15 
 
 
 
Figure 5. Biodistribution in male CD1 mouse after a single i.p. injection of Cy7.5 loaded 50 
nm P(n-BA) nanoparticles (1.2 mg/kg). Distribution was monitored using the 800 nm 
fluorescence channel of a LICOR Pearl® Trilogy. (A) Pharmacokinetic study over 76 h (B) 
Ventral, dorsal and lateral views of a mouse 76 h after injection (C) Ex vivo images of organs 
samples 76 h after injection.  
 
3. Conclusions  
By generating a library of P(PEGA) shell and P(n-BA) and P(t-BA) core nanoparticles, we 
have shown that RAFT emulsion polymerisation is a highly versatile method to synthesise 
biocompatible nanomaterials. Furthermore, this approach is particularly interesting for its 
industrial scale up potential as reactions are performed in environmentally friendly aqueous 
environments, and reach full consumption of cytotoxic monomer within a matter of hours. 
These advantages allow use of the nanoparticles for biological purposes without prior 
purification. The particles displayed no toxicity in our in vitro and in vivo experiments, and 
relatively long retention in mice post administration with high accumulation in the liver. 
Overall, our synthetic approach has the potential to influence future nanoparticle design aimed 
at biomedical applications.  
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4. Experimental  
4.1 Materials 
 
Poly(ethylene glycol) methyl ether acrylate (PEGA, average Mn = 480 g mol
-1), n-butyl 
acrylate (n-BA, >99%) and t-butyl acrylate (t-BA 98%), Bromo-propionic acid (>99%), 1-
butanethiol (99%), carbon disulphide (>99%) and tannic acid (ACS reagent) were obtained 
from Sigma-Aldrich. All monomers above were passed through basic aluminium oxide to 
remove inhibitor before use. Chloroform-d3 (99.8% D atom), was obtained from Sigma Aldrich 
and used for 1H NMR spectroscopy. Thermal initiator 4,4′-azobis(4-cyanovaleric acid) 
(ACVA, >98%, Aldrich), was used as received. Cyanine 7.5 amine was purchased from 
Lumiprobe. TEM grids were purchased from EM Resolutions Ltd (Sheffield, UK). RAFT 
agent, 2-(((butylthio)carbonothioyl)thio)propanoic acid (PABTC) was synthesised as 
previously described.22 
 
4.2 Characterisation methods 
 
4.2.1. 1H NMR spectroscopy 
1H NMR spectra were recorded on a Bruker DPX-250, DPX-300 or DPX-400 spectrometer 
using deuterated solvent (materials section).   
 
4.2.2. Size exclusion chromatography 
SEC was performed using an Agilent 390-LC MDS instrument equipped with differential 
refractive index (DRI), viscometry (VS), dual angle light scatter (LS) and two wavelength UV 
detectors. The system was equipped with 2 x PLgel Mixed C columns (300 x 7.5 mm) and a 
PLgel 5 µm guard column. The eluent was CHCl3 with 2 % TEA (triethylamine) additive. 
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Samples were run at 1 ml/min at 30’C. Poly(methyl methacrylate), and polystyrene standards 
(Agilent EasyVials) were used for calibration. Ethanol was added as a flow rate marker. 
Analyte samples were filtered through a GVHP membrane with 0.22 μm pore size before 
injection. Respectively, experimental molar mass (Mn,SEC) and dispersity (Đ) values of 
synthesized polymers were determined by conventional calibration using Agilent GPC/SEC 
software. 
CTA
M
thn M
CTA
pMM
M 
0
0
,
][
][
 
Equation 1. Calculation of theoretical number average molar mass (Mn,th) where [M]0 and 
[CTA]0 are the initial concentrations (mol dm
-3) of monomer and chain transfer agent 
respectively. p is the monomer conversion as determined by 
1H NMR spectroscopy. MM and 
MCTA are the molar masses (g mol
-1) of the monomer and chain transfer agent respectively. 
 
4.2.3. Dynamic light scattering, size and zeta-potential 
Size and ζ-potential measurements were carried out using a Malvern Zetasizer Nano-ZS at 
25°C with a 4 mW He-Ne 633 nm laser at a scattering angle of 173° (back 
scattering).  Measurements were taken assuming the refractive index of: polyethylene glycol 
for diblock macro-RAFT agents, and the refractive index of the core material (e.g n-butyl 
acrylate or t-butyl acrylate) for latex particles. DLS samples of latex particles were prepared 
by diluting by 1000 with 1 mL of water and measured unfiltered in 1.5 mL polystyrene cuvettes 
for measuring size and a Malvern DTS-1070 zeta cuvette for ζ-potential. Diblock copolymer 
macro-RAFT agent samples were measured at the concentration of a typical RAFT 
emulsion polymerization (15 mg mL-1). Samples were incubated for 60 seconds at 25°C prior 
to measurement. Measurements were repeated three times with automatic attenuation selection 
and measurement position. Results were analysed using Malvern DTS 6.20 
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software. PDi values were calculated using the following equation. Measurements of ζ-
potential were modelled with the Smoluchowski theory.      
2
2
hd
PDi

  
Equation 2. Calculation of nanoparticle polydispersity (PDi) from standard deviation (σ), and 
diameter (d) 
 
4.2.4. Static light scattering 
Static light scattering measurements were performed with an ALV-CGS3 system (ALV-
Langen) operating with a vertically polarized laser with wavelength λ = 632.8 nm. 
Measurements were conducted at 20°C over a range of angles (20, 30, 50, 70, 90, 110, 130 and 
150 degrees) and concentrations in aqueous conditions. Samples were measured unfiltered. The 
intercepts for each concentration of plots for q vs KC/R were then plotted against concentration, 
and the intercept of the latter graph was taken as the apparent molar mass. Full details can be 
found in the supplementary information (Equation S1-S5).  
 
4.2.5. Calculation of the theoretical number of aggregation  
The theoretical number of aggregation was determined, first by evaluating the number of 
particles per unit volume (Np; Equation 3), and then dividing the number of macro-RAFT 
agents per unit volume by this value (Equation 4). 
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  ph
p
dD
N
3
6


  
 
Equation 3. Determination of the number of particles per volume. Np = number of particles per 
mL τ = solids content (g mL-1), Dh = average hydrodynamic particle diameter, dp = density of 
polymeric core.  
p
A
agg
N
NRAFTmacro
N


][
 
 
Equation 4. Number of macro-RAFT agents per particle (Nagg). 
 
4.2.6. Different Refractometry 
Measurements were performed with an RI-101 from Shodex (0=632 nm). The refractive index 
increment was measured in water using 5 concentrations of nanoparticles and the dn/dC was 
calculated by equation S6. 
 
4.2.7. Cryogenic-transmission electron microscopy 
8 µL of the sample was applied to a glow-discharged lacey carbon grid (EM Resolutions), 
blotted for 4 seconds and frozen in liquid propane/ethane (30%/70% v/v) using a custom-made 
plunge-freezing device. Grids were imaged in the JEOL 2200FS with a Gatan K2 camera and 
a Gatan 914 cryo-holder cooled to -180 ˚C.   
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4.2.8. Fluorescence spectroscopy 
Fluorescence emission spectra were measured using an Agilent Cary Eclipse fluorescence 
spectrometer. Studies were performed by exciting at the absorption maxima of Cy7.5 (780 nm) 
and measured from 785 nm to 900 nm. The photomultiplier voltage was set such that the 
maxima was below 1000 arbitrary units. Samples were diluted 1: 100 fold in pure water for 
measurement.  
 
4.3. Synthetic Procedures 
4.3.1 P(PEGA)8 synthesis 
Procedures adapted from literature conditions.33 PABTC (0.31 g, 1.30 x 10-3 mol), PEGA (5 g, 
10.4 x 10-3 mol) and ACVA (from a pre-made stock solution in 1,4-dioxane) (18 mg, 6.51 x 
10-5 mol) were dissolved in 4.9 mL 1,4-dioxane in a 25 mL round bottom flask equipped with 
a magnetic stirrer bar. The solution was fitted with an appropriate sized rubber septum, and 
purged with nitrogen for 20 minutes. The round bottom flask was subsequently immersed in 
an oil bath preheated to 70°C and stirred for 3 h. The reaction vessel was cooled to ambient 
temperature and opened to oxygen to quench further polymerisation. The polymer was purified 
by precipitation into a mixture of 20% hexane and 80% diethyl ether (v/v), collected, and the 
precipitation repeated once more. Finally, the precipitated polymer was dissolved in DCM, 
transferred to a 20 mL vial, the DCM evaporated and dried in a vacuum oven overnight at 40°C 
to yield P(PEGA)8 as a yellow viscous liquid (4.5 g).  
 
4.3.2. Macro-RAFT agent synthesis 
All diblock copolymer macro-RAFT agents were synthesized with the following general 
procedure, as an example P(PEGA)8-P(n-BA)8 is described.
33 Full details can be found in table 
S1. n-Butyl acrylate (0.25 g, 1.95 x 10-3 mol) and 0.68 mL of a 5 mg ml-1 ACVA stock solution 
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in 1,4-dioxane (3.4 mg, 1.21 x 10-5 mol) were added to P(PEGA)8 (0.94 g, 2.43 x 10
-4). The 
polymerisation mixture was purged with nitrogen for 20 minutes and heated to 70°C for 3 h. 
The resulting polymer solution was cooled to room temperature and subsequently purified by 
precipitation in hexane. The yellow viscous liquid was re-dissolved in dichloromethane and 
the precipitation was repeated once more. Finally, the solvent was evaporated under reduced 
pressure to yield the di-block macro-RAFT agent as a yellow viscous liquid (0.95 g).     
 
4.3.3. RAFT emulsion polymerisation procedure 
Nanoparticles of different sizes and core compositions were prepared using previously 
described conditions, full details can be found in Table S2.33 As an example synthesis of 
P(PEGA)8-b-P(t-BA)8-b-P(t-BA)200 is described. 1.43 mL of a 10 mg mL
-1 sodium hydroxide 
stock solution (14.3 mg, 3.6 x 10-4 mol) was added to a suspension of ACVA (50 mg, 1.8 x 10-
4 mol) in water (8.57 mL) and stirred for 30 min to ensure full solubility. P(PEGA)8-b-P(t-BA)8 
(0.145 g, 2.85 x 10-5 mol) was dissolved in 7.71 mL of water, in a 25 mL round bottomed flask 
and equipped with a magnetic stirrer. 1.45 mL of the above ACVA stock solution was added, 
the vial fitted with a rubber septum, and the solution was deoxygenated with dinitrogen gas for 
20 minutes. Deoxygenated t-BA (0.83 mL, 2.14 x10-3 mol) was added via syringe and the 
polymerisation mixture was immersed in a 70°C oil bath and stirred for 3 h at 400 RPM. 
Monomer conversion was determined via gravimetric techniques. 
 
4.3.4. PEG binding assay 
Tannic acid was diluted to a concentration of 10 µg mL-1 in deionised water. Nanoparticle 
suspensions were diluted with deionised water to a concentration of 10 µg mL-1. 1 mL of the 
nanoparticle suspensions were transferred to a polystyrene cuvette and placed in the UV-VIS 
spectrometer. Absorbance measurements were recorded once every 1 s at 500 nm. After 1 min, 
22 
 
250 µL of the tannic acid solution was added via micropipette and mixed briefly without 
allowing the pipette tip into the detection window. The absorption was monitored for a further 
4 minutes. 
 
4.3.5. Encapsulation of Cyanine 7.5 
Cy7.5 (1 mg) was added to 1 mL of 10% DMF in THF and sonicated until the powder had fully 
dissolved. 100 µL of the Cy7.5 solution was added to 900 µL of nanoparticle suspension and 
shaken for 1 h. The suspension was then dialysed (3500-5000 Da MWCO) against pure water 
for 48 h to remove residual DMF and THF. Loaded particles were used immediately after 
encapsulation for in vivo fluorescence studies.  
 
4.4. In vitro studies 
4.4.1. Cell culture 
Caco-2 cells were purchased from ECACC (European Collection of Animal Cell Culture, 
Salisbury, UK; ECACC 86010202) and cultured as monolayers at 37˚C in a humidified 
atmosphere containing 5% CO2. Cells were cultured in a 50:50 mixture of Dulbecco’s Modified 
Eagle Medium (DMEM) and HAMS F12 supplemented with 10% of foetal calf serum, 1 % of 
L-glutamine and 1% penicillin/streptomycin. Cells were sub-cultured at regular intervals and 
passages made by trypsinising cells when at 80-90% confluence. 
 
4.4.2. Cell viability assay 
Caco-2 cells  were seeded at a density of 10,000 cells per well in a flat bottomed clear 96 well 
plate and incubated for 24 h. Nanoparticles were diluted with cell culture medium into a 2 mg 
ml-1 suspension. The stock solution was then serially diluted to make solutions of 100 ng ml-1, 
1 µg ml-1, 10 µg ml-1, 100 µg ml-1, 500 µg ml-1 and 2 mg mL-1. The cells were incubated in the 
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presence of the nanoparticle suspensions for 72 h. The sulforhodamine B assay was used to 
determine cell viability as a function of biomass fixed on the well plate surface, relative to 
untreated controls. In short, 50 µL of cold 50% trifluoroacetic acid were added to each well of 
the plate and left to incubate for 1 h at 4°C, the plate was subsequently washed 10 times with 
slow running tap water to remove excess trifluoroacetic acid. Then, the plate was heated gently 
with warm air to remove moisture, and 50 µL of 0.4% sulforhodamine B (prepared in 1% acetic 
acid) were added to each well and incubated at ambient temperature for 30 min. Excess dye 
was removed by washing the plate 5 times with 1% acetic acid. Finally, 200 µL of 10 mM Tris 
base solution (pH 10.5) were added to each well and incubated at ambient temperature for 1 h 
before absorbance of each well was measured at 570 nm on a BioRad iMark 96-well microplate 
reader. All experiments were carried out as duplicates of triplicates in two independent 
experiments (N=6). 
 
4.5. In vivo studies 
4.5.1. Animal handling 
All in vivo studies were conducted on adult male CD1 mice purchased from Charles River 
(UK). Upon arrival, mice were allowed to adjust to the new environmental condition for at 
least two weeks. Humidity and temperature were kept between 45 to 60% and between 20 to 
24°C, respectively, and animals had 12 hours of light per with light onset at 07:00. Mice had 
ad libitum access to food and water. All in vivo experiments were carried out in accordance 
with the Animal Scientific Procedure Act 1986 under the Procedure Project Licence (PPL) 
number 70/3685.  
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4.5.2. In vivo toxicity studies 
For acute, single dose toxicity evaluation, 29 six to seven week old male mice were randomised 
into eight groups and intraperitoneally (i.p.) injected with the different nanoparticles 
(N=3/group), vehicle (PBS, N=3) or nothing (N=2). Nanoparticle groups were injected with 49 
and 86 nm P(t-BA), and 50 and 93 nm P(n-BA) nanoparticles at either 1.2 mg kg-1 (0.2 mg ml-
1 in 200 µl PBS) or 12 mg kg-1 (2 mg ml-1 in 200 µl PBS). Of note, nanoparticle dilutions were 
prepared in sterile PBS under aseptic conditions and stored at 2 to 8°C until treatment. After 
injection, mice were monitored daily for the following 7 days and body weight as well as signs 
of pain or distress were recorded.  
 
For the repeat dosing study, 35 six to seven weeks old male mice were randomised into four 
nanoparticle treatment groups (N=6/groups) and 2 control groups (PBS N=3; no-injection N=2) 
as described above. Each mouse was i.p. injected daily with 12 mg kg-1 (200 µl of 2 mg ml-1) 
of one of 4 types of nanoparticles, i.e. 49 or 86 nm of P(t-BA) or, 50 or 93 nm of P(n-BA), or 
PBS for five consecutive days. The second control group received no injection. After the first 
injection, mice were monitored daily for the following 8 days and body weight as well as signs 
of pain or distress were recorded. Data was analysed with a two-way ANOVA with repeated 
measures. 
 
4.5.3. In vivo biodistribution 
For biodistribution studies, mice were injected intraperitoneally with a single dose of Cy 7.5 
labelled P(n-BA) 50 nm nanoparticles (1.2 mg kg-1). Fluorescence was recorded using a 
LICOR Pearl® Trilogy in vivo imager in the 800 nm channel in intervals for up to 76 h post 
injection. Kinetic in vivo fluorescence profiles were obtained by quantifying the total 
fluorescence of one region of interest encompassing the whole animal using open access 
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software Image Studio LiteTM. Organs were excised and imaged immediately after euthanasia 
with anaesthetic overdose. Organ fluorescence/unit area was established by drawing around 
each organ and dividing this value by the area reported in the software.  
 
Supporting Information 
Supporting Information is available from the Wiley Online Library  
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RAFT emulsion polymerization to produce biocompatible PEGylated nanoparticles is 
reported. This synthesis approach allows for different core composition and particle sizes to be 
synthesized. The nanoparticles were highly tolerated in vitro and in vivo, with no inherent 
toxicity observed after multiple injections, and biodistribution studies showing high 
nanoparticle accumulation in the liver.  
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